{"blog": [], "keywords": [{"value": "Valeant Pharmaceuticals International Inc", "name": "organizations", "rank": "1", "is_major": "Y"}, {"value": "Papa, Joseph C", "name": "persons", "rank": "2", "is_major": "Y"}, {"value": "Company Reports", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "4", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/06/08/business/valeant-q1-earnings.html", "document_type": "article", "byline": {"person": [{"lastname": "THOMAS", "firstname": "Katie", "role": "reported", "organization": "", "rank": 1}], "original": "By KATIE THOMAS"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/06/08/business/08valeant/08valeant-thumbWide.jpg", "legacy": {"wide": "images/2016/06/08/business/08valeant/08valeant-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/06/08/business/08valeant/08valeant-articleLarge.jpg", "legacy": {"xlarge": "images/2016/06/08/business/08valeant/08valeant-articleLarge.jpg", "xlargeheight": "400", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 400}, {"url": "images/2016/06/08/business/08valeant/08valeant-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/06/08/business/08valeant/08valeant-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "797", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "Valeant, the pharmaceuticals company facing questions about its business and accounting practices, said it lost nearly $374 million in the quarter.", "pub_date": "2016-06-08T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "Valeant Reports First-Quarter Loss as Chief Assures Bright Future", "main": "Valeant Reports First-Quarter Loss and Cuts Its Forecast"}, "print_page": "2", "snippet": "Valeant, the pharmaceuticals company facing questions about its business and accounting practices, said it lost nearly $374 million in the quarter.", "_id": "5756d0a038f0d839b19249f9", "slideshow_credits": null, "abstract": "Valeant Pharmaceuticals chief executive Joseph C Papa tells analysts that he is optimistic about company's future; company reports loss of almost $374 million in first quarter, revealing troubles in its core business areas."}